Minireviews
Copyright ©The Author(s) 2015.
World J Hepatol. Jul 28, 2015; 7(15): 1953-1963
Published online Jul 28, 2015. doi: 10.4254/wjh.v7.i15.1953
Table 1 Chronologically listed, Food and Drug Administration approved treatment regimens for hepatitis C virus
HCV (identified in 1989)
Approved drugs 1991-2001
Interferon (approved in 1991)
RBV + standard interferon (1998)
Peg-IFNs (approved in 2001)
Peg-IFN
Peg-IFN + RBV
DAAs 2011-present
Telaprevir and boceprevir
Increase SVR rates and provide the option of response-guided therapy and retreatment for genotype 1 patients
Telaprevir + peg-IFN + RBV, genotype 1 only (2011)
Boceprevir + peg-IFN + RBV, genotype 1 only (2011)
Sofosbuvir
Approved for use in all genotypes. High SVR rates with better tolerability, shorter duration, use in HIV-HCV co-infection, and first interferon-free all-oral regimen in genotype 2, 3 and certain other patients
Sofosbuvir + peg-IFN + RBV, in genotype 1 only (2013)
Sofosbuvir + RBV, without interferon, in genotype 2 and 3, in HIV-HCV co-infection, with any genotype, and in selected situations of genotype 1 (2013)
Simeprevir
High SVR rates with better tolerability and shorter duration for genotype 1
Simeprevir + peg-IFN + RBV, in genotype 1 only (2013)
Adapted from http://www.hepatitis.va.gov. DAAs: Direct acting antivirals; SVR: Sustained virological response; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; RBV: Ribavirin; Peg-IFN: Pegylated interferon.